SE448324B - Sett vid immunkemisk bestemning av lipoproteiner och apolipoproteiner - Google Patents

Sett vid immunkemisk bestemning av lipoproteiner och apolipoproteiner

Info

Publication number: SE448324B
Authority: SE; Sweden
Prior art keywords: pretreatment step; apo; serum; determination; adjusted
Prior art date: 1985-09-27

Application number

SE8504466A

Other languages

English (en)

Swedish (sv)

Other versions

SE8504466D0 (sv

Inventor

G B Jansson

S E Holmlund

Original Assignee

Pharmacia Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-09-27

Filing date

1985-09-27

Publication date

1987-02-09

1985-09-27 Application filed by Pharmacia Ab filed Critical Pharmacia Ab

1985-09-27 Priority to SE8504466A priority Critical patent/SE448324B/sv

1985-09-27 Publication of SE8504466D0 publication Critical patent/SE8504466D0/xx

1986-09-12 Priority to DE8686905968T priority patent/DE3675763D1/de

1986-09-12 Priority to AU64039/86A priority patent/AU590340B2/en

1986-09-12 Priority to AT86905968T priority patent/ATE58599T1/de

1986-09-12 Priority to EP86905968A priority patent/EP0238614B1/fr

1986-09-12 Priority to PCT/SE1986/000405 priority patent/WO1987002137A1/fr

1986-09-12 Priority to US07/049,997 priority patent/US4877746A/en

1986-09-12 Priority to JP61505181A priority patent/JPS63501037A/ja

1986-09-26 Priority to ES8602242A priority patent/ES2002004A6/es

1986-09-26 Priority to CA000519195A priority patent/CA1280070C/fr

1987-02-09 Publication of SE448324B publication Critical patent/SE448324B/sv

Links

108090001030 Lipoproteins Proteins 0.000 title claims description 13
108010071619 Apolipoproteins Proteins 0.000 title claims description 12
102000007592 Apolipoproteins Human genes 0.000 title claims description 12
102000004895 Lipoproteins Human genes 0.000 title claims description 12
238000000034 method Methods 0.000 claims description 26
102100040214 Apolipoprotein(a) Human genes 0.000 claims description 14
101710115418 Apolipoprotein(a) Proteins 0.000 claims description 14
230000000984 immunochemical effect Effects 0.000 claims description 13
238000012360 testing method Methods 0.000 claims description 11
230000000890 antigenic effect Effects 0.000 claims description 6
230000008105 immune reaction Effects 0.000 claims 1
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
210000002966 serum Anatomy 0.000 description 15
239000000523 sample Substances 0.000 description 12
239000000872 buffer Substances 0.000 description 7
238000010790 dilution Methods 0.000 description 7
239000012895 dilution Substances 0.000 description 7
239000008363 phosphate buffer Substances 0.000 description 7
238000002203 pretreatment Methods 0.000 description 6
239000000243 solution Substances 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
239000000725 suspension Substances 0.000 description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
239000000126 substance Substances 0.000 description 4
241000283707 Capra Species 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000003139 buffering effect Effects 0.000 description 3
239000003599 detergent Substances 0.000 description 3
230000028993 immune response Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000004471 Glycine Substances 0.000 description 2
239000004367 Lipase Substances 0.000 description 2
102000004882 Lipase Human genes 0.000 description 2
108090001060 Lipase Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
239000002253 acid Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
229960004198 guanidine Drugs 0.000 description 2
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000002427 irreversible effect Effects 0.000 description 2
235000019421 lipase Nutrition 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
238000011002 quantification Methods 0.000 description 2
239000000376 reactant Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000010998 test method Methods 0.000 description 2
241000428352 Amma Species 0.000 description 1
102000006410 Apoproteins Human genes 0.000 description 1
108010083590 Apoproteins Proteins 0.000 description 1
101100129921 Bacillus subtilis (strain 168) melE gene Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
108010004103 Chylomicrons Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
241000408495 Iton Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
101100292249 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) msmE gene Proteins 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
241000700605 Viruses Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
208000037919 acquired disease Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
239000012670 alkaline solution Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000005515 coenzyme Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical group BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
238000000326 densiometry Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
230000000951 immunodiffusion Effects 0.000 description 1
239000003547 immunosorbent Substances 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
239000002523 lectin Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
239000003973 paint Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
OFSDTGZOZPQDCK-UHFFFAOYSA-N polane Chemical compound [PoH2] OFSDTGZOZPQDCK-UHFFFAOYSA-N 0.000 description 1
229910000035 polane Inorganic materials 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
229910000406 trisodium phosphate Inorganic materials 0.000 description 1
235000019801 trisodium phosphate Nutrition 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/804—Radioisotope, e.g. radioimmunoassay
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/825—Pretreatment for removal of interfering factors from sample

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Endocrinology (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

SE8504466A 1985-09-27 1985-09-27 Sett vid immunkemisk bestemning av lipoproteiner och apolipoproteiner SE448324B (sv)

Priority Applications (10)

Application Number	Priority Date	Filing Date	Title
SE8504466A SE448324B (sv)	1985-09-27	1985-09-27	Sett vid immunkemisk bestemning av lipoproteiner och apolipoproteiner
JP61505181A JPS63501037A (ja)	1985-09-27	1986-09-12	リポタンパク質及びアポリポタンパク質の測定方法
EP86905968A EP0238614B1 (fr)	1985-09-27	1986-09-12	Procedes d'analyses pour detecter des lipoproteines et des apolipoproteines
AU64039/86A AU590340B2 (en)	1985-09-27	1986-09-12	Methods of carrying out assays for lipoproteins and apolipoproteins
AT86905968T ATE58599T1 (de)	1985-09-27	1986-09-12	Testverfahren fuer lipoproteine und apolipoproteine.
DE8686905968T DE3675763D1 (de)	1985-09-27	1986-09-12	Testverfahren fuer lipoproteine und apolipoproteine.
PCT/SE1986/000405 WO1987002137A1 (fr)	1985-09-27	1986-09-12	Procedes d'analyses pour detecter des lipoproteines et des apolipoproteines
US07/049,997 US4877746A (en)	1985-09-27	1986-09-12	Methods of carrying out assays for lipoproteins and apolipoproteins
ES8602242A ES2002004A6 (es)	1985-09-27	1986-09-26	Procedimiento para llevar a cabo el analisis inmunoquimico de lipoproteinas y-o apolipoproteinas
CA000519195A CA1280070C (fr)	1985-09-27	1986-09-26	Methode de dosage de lipoproteines et d'apolipoproteines

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE8504466A SE448324B (sv)	1985-09-27	1985-09-27	Sett vid immunkemisk bestemning av lipoproteiner och apolipoproteiner

Publications (2)

Publication Number	Publication Date
SE8504466D0 SE8504466D0 (sv)	1985-09-27
SE448324B true SE448324B (sv)	1987-02-09

Family

ID=20361533

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8504466A SE448324B (sv)	1985-09-27	1985-09-27	Sett vid immunkemisk bestemning av lipoproteiner och apolipoproteiner

Country Status (9)

Country	Link
US (1)	US4877746A (fr)
EP (1)	EP0238614B1 (fr)
JP (1)	JPS63501037A (fr)
AU (1)	AU590340B2 (fr)
CA (1)	CA1280070C (fr)
DE (1)	DE3675763D1 (fr)
ES (1)	ES2002004A6 (fr)
SE (1)	SE448324B (fr)
WO (1)	WO1987002137A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2627589B1 (fr) *	1988-02-24	1995-06-09	Pasteur Institut	Procede immunoenzymometrique selectif pour le dosage de lipoproteines contenant de l'apob ou un fragment de celle-ci, anticorps monoclonaux anti-lp(a) et application au diagnostic de l'atherosclerose
JPH02242158A (ja) *	1989-03-15	1990-09-26	Nippon Shoji Kk	ヒトアポリポ蛋白ｃ―３の測定法
US5473039A (en) *	1989-08-18	1995-12-05	The Scripps Research Institute	Polypeptide analogs of apolipoprotein E, diagnostic systems and methods using the analogs
US5168045A (en) *	1989-08-18	1992-12-01	The Scripps Research Institute	Diagnostic systems and methods using polypeptide analogs of apolipoprotein e
US5262303A (en) *	1989-10-13	1993-11-16	Trustees Of Boston University	Ligand/anti-ligand assays for adherent proteins
US5149501A (en) *	1990-01-29	1992-09-22	Cirrus Diagnostics, Inc.	Multichambered container and instrument for performing diagnostic tests
CA2052316C (fr) *	1990-10-10	1997-12-23	Edward A. Oakley	Systeme de mesure de l'ecoulement des boues
AU9088891A (en) *	1990-11-29	1992-06-25	John E. Carbaugh	Diagnostic and therapeutic compositions and methods for lipoprotein(a)
US5844097A (en) *	1990-11-30	1998-12-01	Monoclonetics International, Inc.	Methods for the diagnosis of peripheral nerve damage
ES2083152T3 (es) *	1990-11-30	1996-04-01	Monoclonetics Int	Metodos para el diagnostico de dolores cronicos lumbares y cervicales.
WO1992021015A1 (fr) *	1991-05-23	1992-11-26	Seman Leo J Jr	PROCEDE DE DETECTION DE LIPOPROTEINE (a) ET DE CHOLESTEROL ASSOCIE A CELLE-CI
AU672028B2 (en) *	1992-08-14	1996-09-19	Shino-Test Corporation	Peptides containing respective amino acid sequences selected from among those of lipoprotein(a) and apolipoprotein(a), antibodies respectively recognizing these amino acid sequences, and method of assaying with these antibodies
WO1995009363A1 (fr) *	1993-09-29	1995-04-06	Yamasa Corporation	Procede de titrage de lipoproteine oxydee et applications de ce procede
GB0001089D0 (en) *	2000-01-18	2000-03-08	Council Cent Lab Res Councils	Lipoprotein assay
ATE309544T1 (de)	2002-04-09	2005-11-15	Cholestech Corp	Verfahren und vorrichtung zur quantifizierung von lipoprotein-cholesterol hoher dichte
JP3600231B1 (ja) *	2003-09-30	2004-12-15	森永製菓株式会社	イムノアッセイ
EP2126587B1 (fr)	2007-01-09	2010-09-29	Cholestech Corporation	Dispositif et procédé de mesure du cholestérol associé au ldl

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2829531A1 (de) *	1978-07-05	1980-01-24	Heuck Claus Christian Dr Rer N	Verfahren zur quantitativen bestimmung eines serumproteins in getruebten serum- und plasma-proben
JPS58166263A (ja) *	1982-03-27	1983-10-01	Dai Ichi Pure Chem Co Ltd	アポ蛋白ａ−ｉ標準品の調製法
DE3323949A1 (de) *	1983-07-02	1985-01-03	Boehringer Mannheim Gmbh, 6800 Mannheim	Verfahren und mittel zur raschen und vollstaendigen beseitigung einer truebung in einer biologischen fluessigkeit
JPS6015559A (ja) *	1983-07-06	1985-01-26	Shiraimatsu Shinyaku Kk	アポリポ蛋白−ｂの酵素免疫測定試薬
DE3338836A1 (de) *	1983-10-26	1985-05-09	Boehringer Mannheim Gmbh	Verfahren zur bestimmung der low density lipoproteine (ldl) und reagenz zu seiner durchfuehrung
DE3533288A1 (de) *	1985-09-18	1987-03-26	Boehringer Mannheim Gmbh	Verfahren und reagenz zur spezifischen bestimmung von hdl-cholesterin im serum

1985
- 1985-09-27 SE SE8504466A patent/SE448324B/sv not_active IP Right Cessation
1986
- 1986-09-12 US US07/049,997 patent/US4877746A/en not_active Expired - Fee Related
- 1986-09-12 JP JP61505181A patent/JPS63501037A/ja active Pending
- 1986-09-12 EP EP86905968A patent/EP0238614B1/fr not_active Expired - Lifetime
- 1986-09-12 AU AU64039/86A patent/AU590340B2/en not_active Ceased
- 1986-09-12 WO PCT/SE1986/000405 patent/WO1987002137A1/fr not_active Ceased
- 1986-09-12 DE DE8686905968T patent/DE3675763D1/de not_active Expired - Fee Related
- 1986-09-26 CA CA000519195A patent/CA1280070C/fr not_active Expired - Fee Related
- 1986-09-26 ES ES8602242A patent/ES2002004A6/es not_active Expired

Also Published As

Publication number	Publication date
JPS63501037A (ja)	1988-04-14
AU590340B2 (en)	1989-11-02
EP0238614B1 (fr)	1990-11-22
CA1280070C (fr)	1991-02-12
WO1987002137A1 (fr)	1987-04-09
AU6403986A (en)	1987-04-24
EP0238614A1 (fr)	1987-09-30
ES2002004A6 (es)	1988-07-01
DE3675763D1 (de)	1991-01-03
US4877746A (en)	1989-10-31
SE8504466D0 (sv)	1985-09-27

Legal Events

Date

Code

Title

Description

1995-01-31

NUG

Patent has lapsed

Ref document number: 8504466-7

Effective date: 19880622

Format of ref document f/p: F

Publication	Publication Date	Title
SE448324B (sv)	1987-02-09	Sett vid immunkemisk bestemning av lipoproteiner och apolipoproteiner
Park et al.	1996	Plasma lipopolysaccharide-binding protein is found associated with a particle containing apolipoprotein AI, phospholipid, and factor H-related proteins
US5344758A (en)	1994-09-06	Methods for determining anti-phospholipid and anti-cardiolipin antibodies
Porcheron et al.	1989	Development of an enzyme immunoassay for ecdysteroids using acetylcholinesterase as label
US4145406A (en)	1979-03-20	Specific binding - adsorbent assay method and test means
von Zychlinski et al.	2011	Proteomics of Lipoprotein (a) identifies a protein complement associated with response to wounding
Obama et al.	2007	Analysis of modified apolipoprotein B‐100 structures formed in oxidized low‐density lipoprotein using LC‐MS/MS
CA1146067A (fr)	1983-05-10	Methode de dosage immunologique en phase solide utilisant un anticorps anti-haptene marque
Acton et al.	1971	Isolation and characterization of the immune macroglobulin from the paddlefish, Polyodon spathula
Cheung et al.	1979	Direct solid phase radioimmunoassay for chicken lipoprotein lipase
Schenkein et al.	2001	Phosphorylcholine-dependent cross-reactivity between dental plaque bacteria and oxidized low-density lipoproteins
Hrafnsdóttir et al.	2000	Reconstitution and partial characterization of phospholipid flippase activity from detergent extracts of the Bacillus subtilis cell membrane
Koren et al.	1985	Quantitative determination of human plasma apolipoprotein AI by a noncompetitive enzyme-linked immunosorbent assay
Lagrost	1998	Determination of the mass concentration and the activity of the plasma cholesteryl ester transfer protein (CETP)
Osman et al.	1995	A sensitive time-resolved immunofluorometric assay for the measurement of apolipoprotein B in cerebrospinal fluid. Application to multiple sclerosis and other neurological diseases
Beghin et al.	2000	Measurement of apolipoprotein B concentration in plasma lipoproteins by combining selective precipitation and mass spectrometry
Bensadoun	1996	[23] Sandwich immunoassay for measurement of human hepatic lipase
O'Connor et al.	1997	Measurement of prebeta-1 HDL in human plasma by an ultrafiltration-isotope dilution technique
WO1989001164A1 (fr)	1989-02-09	Procede d'immuno-analyse d'apolipoproteines
Case et al.	1999	Enhanced ultrasensitive detection of structurally diverse antigens using a single immuno-PCR assay protocol
Gambino et al.	1999	The binding of apolipoprotein H (β2-glycoprotein I) to lipoproteins
Eriksen et al.	1986	[16] Serum amyloid A (ApoSAA) and lipoproteins
Schwalbe et al.	1995	Association of rat C-reactive protein and other pentraxins with rat lipoproteins containing apolipoproteins E and A1
EP0080108B1 (fr)	1986-10-08	Réactif diagnostique et son utilisation
Gustafson et al.	1984	A rapid radioimmunoassay of human apolipoproteins C-II and C-III